Market Analysis and Price Projections for the Drug NDC: 0641-6135
Introduction
The drug with the National Drug Code (NDC) 0641-6135, identified as Prochlorperazine Edisylate Injection, is a human prescription drug manufactured by Hikma Pharmaceuticals USA Inc. This analysis will delve into the market dynamics, pricing trends, and projections for this specific drug.
Market Context
Prescription Drug Market Overview
The prescription drug market in the U.S. is characterized by high prices and frequent price increases, which pose significant affordability challenges for patients, healthcare payers, and taxpayers. According to the ASPE brief, high prescription drug prices have been a persistent issue, with many drugs experiencing price increases exceeding the rate of inflation[4].
Specific Drug Category
Prochlorperazine Edisylate Injection falls under the category of antiemetic and antipsychotic medications. This class of drugs is crucial for treating various conditions, including nausea, vomiting, and psychiatric disorders.
Pricing Trends
Historical Price Changes
To understand the pricing trends for Prochlorperazine Edisylate Injection, it is essential to look at historical data. The ASPE brief indicates that from January 2022 to January 2023, more than 4,200 drug products had price increases, with 46% of these increases being larger than the rate of inflation. The average drug price increase during this period was 15.2%, translating to $590 per drug product[4].
NDC-Specific Data
While specific historical price data for NDC 0641-6135 is not provided in the sources, it is likely that this drug has followed similar trends as other prescription drugs. Given its classification as a human prescription drug with an Abbreviated New Drug Application (ANDA), it may have experienced price adjustments in line with market and regulatory conditions.
Regulatory Environment
FDA and NDC Directory
The FDA's National Drug Code Directory plays a crucial role in tracking and regulating drug products, including those like Prochlorperazine Edisylate Injection. Drug establishments are required to provide the FDA with a current list of all drugs manufactured, prepared, propagated, compounded, or processed for sale in the U.S., using the unique NDC identifier[1].
Medicare and Drug Price Negotiations
The Medicare Drug Price Negotiation Program, set to begin in January 2026, aims to reduce prescription drug costs by negotiating prices for certain high-cost drugs. While Prochlorperazine Edisylate Injection may not be among the initial drugs selected for negotiation, the broader impact of this program on the pharmaceutical market could influence pricing strategies for all prescription drugs[2].
Market Projections
General Market Trends
The pharmaceutical market is expected to see significant changes driven by technological advancements, regulatory shifts, and economic pressures. For instance, the adoption of artificial intelligence (AI) in clinical development and data analysis is predicted to increase, which could impact drug pricing by optimizing production and reducing costs[3].
Specific Projections for Prochlorperazine Edisylate Injection
Given the lack of specific data on price changes for NDC 0641-6135, projections must be based on general trends:
- Price Stability: If the drug is not subject to significant market or regulatory changes, it may experience price stability or moderate increases in line with inflation.
- Potential Decreases: If the Medicare Drug Price Negotiation Program or other regulatory initiatives lead to a broader reduction in prescription drug prices, Prochlorperazine Edisylate Injection could see a decrease in its list price.
- Market Competition: The presence of generic or alternative treatments could also influence pricing. If competitors reduce their prices, Hikma Pharmaceuticals may need to adjust the price of Prochlorperazine Edisylate Injection to remain competitive.
Impact of External Factors
Economic and Regulatory Changes
Economic conditions, such as inflation and changes in healthcare policies, can significantly impact drug pricing. For example, the ASPE brief highlights that price increases for prescription drugs often exceed the rate of inflation, contributing to affordability challenges[4].
Technological Advancements
The increasing use of AI and health tech in the pharmaceutical industry could lead to more efficient production processes and better data-driven decision-making, potentially stabilizing or reducing drug prices[3].
Key Takeaways
- Pricing Trends: Prescription drugs, including Prochlorperazine Edisylate Injection, have historically experienced price increases, often exceeding inflation.
- Regulatory Environment: The FDA's NDC Directory and initiatives like the Medicare Drug Price Negotiation Program play crucial roles in regulating and potentially reducing drug prices.
- Market Projections: Projections for Prochlorperazine Edisylate Injection are based on general market trends, with potential for price stability, decreases due to regulatory changes, or adjustments based on market competition.
- External Factors: Economic conditions, regulatory changes, and technological advancements will continue to influence the pricing of prescription drugs.
FAQs
What is the National Drug Code (NDC) and its significance?
The National Drug Code (NDC) is a unique, three-segment number that serves as the FDA’s identifier for drugs. It is crucial for tracking and regulating drug products in the U.S.[1].
How do regulatory changes impact prescription drug prices?
Regulatory changes, such as the Medicare Drug Price Negotiation Program, can significantly reduce prescription drug prices by negotiating lower prices for high-cost drugs, which may have a broader impact on the market[2].
What role does AI play in the pharmaceutical industry?
AI is increasingly adopted in the pharmaceutical industry for standard operations in clinical development, training internal data science models, and addressing complex topics like the probability of technical and regulatory success[3].
How often do prescription drug prices change?
Prescription drug prices can change frequently, with over 4,200 drug products experiencing price increases from January 2022 to January 2023 alone[4].
What are the main challenges posed by high prescription drug prices?
High prescription drug prices create affordability challenges for patients, healthcare payers, employers, and taxpayers, exacerbated by frequent price increases[4].
Sources
- FDA's National Drug Code Directory - FDA
- Medicare Drug Price Negotiation Program - ASPE - HHS.gov
- 2025 Pharma Predictions: AI, Health Tech, and Data Trends to Watch - Intelligencia.ai
- Changes in the List Prices of Prescription Drugs, 2017-2023 - ASPE - HHS.gov
- Label: PROCHLORPERAZINE EDISYLATE injection - DailyMed
